BRPI0416870A - composições anticáncer sinergìticas - Google Patents
composições anticáncer sinergìticasInfo
- Publication number
- BRPI0416870A BRPI0416870A BRPI0416870-4A BRPI0416870A BRPI0416870A BR PI0416870 A BRPI0416870 A BR PI0416870A BR PI0416870 A BRPI0416870 A BR PI0416870A BR PI0416870 A BRPI0416870 A BR PI0416870A
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- antineoplastic
- synergistically
- synergistic
- combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"COMPOSIçõES ANTICáNCER SINERGìTICAS". A presente invenção refere-se a composições utilizáveis em tratamento de câncer. As composições incluem uma combinação sinergística de um oxidante mitocondrial ligando tiol antineoplásico com um agente de ligação de ácido nucléico antineoplásico, um análogo de base antimetabolita antineoplásico, ou docetaxel. Também são providos os métodos de teste dos efeitos sinergísticos das combinações e métodos de tratamento de câncer usando as combinações sinergísticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52818103P | 2003-12-08 | 2003-12-08 | |
PCT/US2004/041093 WO2005055952A2 (en) | 2003-12-08 | 2004-12-08 | Synergistic anti-cancer compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0416870A true BRPI0416870A (pt) | 2007-01-30 |
Family
ID=34676825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0416870-4A BRPI0416870A (pt) | 2003-12-08 | 2004-12-08 | composições anticáncer sinergìticas |
Country Status (13)
Country | Link |
---|---|
US (3) | US20050176696A1 (pt) |
EP (1) | EP1691801A4 (pt) |
JP (1) | JP2007513202A (pt) |
KR (1) | KR20060103947A (pt) |
CN (1) | CN1889943A (pt) |
AU (1) | AU2004296863B2 (pt) |
BR (1) | BRPI0416870A (pt) |
CA (1) | CA2548491A1 (pt) |
IL (1) | IL175665A0 (pt) |
MX (1) | MXPA06006291A (pt) |
NZ (1) | NZ547252A (pt) |
WO (1) | WO2005055952A2 (pt) |
ZA (1) | ZA200604579B (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008063778A2 (en) * | 2006-10-12 | 2008-05-29 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Synergistic combinations of antineoplastic thiol-binding mitochondrial oxidants and antineoplastic corticosteriods for the treatment of cancer |
WO2008139271A2 (en) * | 2007-05-15 | 2008-11-20 | Piramal Life Sciences Limited | A synergistic pharmaceutical combination for the treatment of cancer |
CN101903029B (zh) * | 2007-11-02 | 2012-09-26 | Zio医药肿瘤学公司 | 使用有机砷化物的联合治疗 |
TWI492759B (zh) * | 2008-03-05 | 2015-07-21 | Otsuka Pharma Co Ltd | 膽甾烷醇衍生物之併用用途 |
TW201300105A (zh) | 2011-05-31 | 2013-01-01 | Piramal Life Sciences Ltd | 治療頭頸鱗狀細胞癌之相乘藥物組合物 |
US9744175B2 (en) | 2012-04-06 | 2017-08-29 | Indus Pharmaceuticals, Inc. | Compositions of combinations of non-covalent DNA binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment |
TWI680760B (zh) | 2013-07-12 | 2020-01-01 | 印度商皮拉馬爾企業有限公司 | 治療黑色素瘤的藥物組合 |
JP6787792B2 (ja) * | 2014-05-23 | 2020-11-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がんの処置のための併用治療 |
CN104267188B (zh) * | 2014-08-28 | 2015-12-30 | 汪建平 | 针对msk1基因的相关制剂在制备5-fu耐药性检测试剂及5-fu耐药逆转剂方面的应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4727046A (en) * | 1986-07-16 | 1988-02-23 | Fairchild Semiconductor Corporation | Method of fabricating high performance BiCMOS structures having poly emitters and silicided bases |
US5369119A (en) * | 1988-07-28 | 1994-11-29 | Boehringer Mannheim Gmbh | Use of imexon as an immune suppressive and pharmaceutical compositions containing imexon |
DE3825667A1 (de) * | 1988-07-28 | 1990-03-15 | Boehringer Mannheim Gmbh | Verwendung von imexon als immunsuppressivum |
DE3841879A1 (de) * | 1988-12-13 | 1990-06-21 | Boehringer Mannheim Gmbh | Neue imidazolidin-derivate, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
PH31594A (en) * | 1993-09-30 | 1998-11-03 | Janssen Pharmaceutica Nv | Oral formulations on an antifungal. |
UA57734C2 (uk) * | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
US6005097A (en) * | 1996-06-14 | 1999-12-21 | Vion Pharmaceuticals, Inc. | Processes for high-yield diastereoselective synthesis of dideoxynucleosides |
US5767134A (en) * | 1997-05-15 | 1998-06-16 | Vion Pharmaceuticals, Inc. | Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP |
US5869676A (en) * | 1997-05-15 | 1999-02-09 | Vion Pharmaceuticals, Inc. | Process for the synthesis of ribonucleotide reductase inhibitors 3-AP and 3-AMP |
GB9713149D0 (en) * | 1997-06-21 | 1997-08-27 | Pfizer Ltd | Pharmaceutical formulations |
ES2210774T3 (es) * | 1997-06-27 | 2004-07-01 | Amplimed, Inc. | Nuevas cianoaziridinas para el tratamiento del cancer. |
AU1172502A (en) * | 2000-10-13 | 2002-04-22 | Vion Pharmaceuticals Inc | Modified prodrug forms of ap/amp |
US20030129222A1 (en) * | 2000-11-21 | 2003-07-10 | Gabriel Lopez-Berestein | Liposomal imexon |
WO2002041871A2 (en) * | 2000-11-21 | 2002-05-30 | Board Of Regents, The University Of Texas System | Composition comprising an imexon or derivatives thereof and lipids |
US6476236B1 (en) * | 2001-11-26 | 2002-11-05 | The Arizona Board Of Regents | Synthesis of 2-cyanoaziridine-1-carboxamide |
-
2004
- 2004-12-08 CN CNA2004800363620A patent/CN1889943A/zh active Pending
- 2004-12-08 AU AU2004296863A patent/AU2004296863B2/en not_active Ceased
- 2004-12-08 CA CA002548491A patent/CA2548491A1/en not_active Abandoned
- 2004-12-08 ZA ZA200604579A patent/ZA200604579B/en unknown
- 2004-12-08 JP JP2006543951A patent/JP2007513202A/ja not_active Withdrawn
- 2004-12-08 KR KR1020067013504A patent/KR20060103947A/ko not_active Application Discontinuation
- 2004-12-08 WO PCT/US2004/041093 patent/WO2005055952A2/en active Application Filing
- 2004-12-08 NZ NZ547252A patent/NZ547252A/en unknown
- 2004-12-08 US US11/007,988 patent/US20050176696A1/en not_active Abandoned
- 2004-12-08 EP EP04813416A patent/EP1691801A4/en not_active Withdrawn
- 2004-12-08 MX MXPA06006291A patent/MXPA06006291A/es active IP Right Grant
- 2004-12-08 BR BRPI0416870-4A patent/BRPI0416870A/pt not_active IP Right Cessation
-
2006
- 2006-05-16 IL IL175665A patent/IL175665A0/en unknown
-
2007
- 2007-12-06 US US11/951,604 patent/US20080153891A1/en not_active Abandoned
- 2007-12-06 US US11/951,638 patent/US20080146653A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2004296863B2 (en) | 2008-12-11 |
JP2007513202A (ja) | 2007-05-24 |
MXPA06006291A (es) | 2006-08-23 |
CA2548491A1 (en) | 2005-06-23 |
IL175665A0 (en) | 2008-04-13 |
WO2005055952A2 (en) | 2005-06-23 |
NZ547252A (en) | 2008-09-26 |
US20080146653A1 (en) | 2008-06-19 |
EP1691801A2 (en) | 2006-08-23 |
AU2004296863A1 (en) | 2005-06-23 |
US20080153891A1 (en) | 2008-06-26 |
KR20060103947A (ko) | 2006-10-04 |
CN1889943A (zh) | 2007-01-03 |
ZA200604579B (en) | 2007-10-31 |
US20050176696A1 (en) | 2005-08-11 |
WO2005055952A3 (en) | 2005-12-15 |
EP1691801A4 (en) | 2009-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0622054B8 (pt) | composto e composição farmacêutica | |
BRPI0611717A2 (pt) | composto, composiÇço farmacÊutica e uso do composto | |
BRPI0509927A (pt) | composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina | |
BRPI0414908A (pt) | compostos de benzazóis substituìdos, composições e métodos de inibição da atividade raf quinase em um humano ou animal | |
BRPI0607809A2 (pt) | uso de uma composição compreendendo nanopartìculas, composição e kit | |
TR200102020T2 (tr) | Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler. | |
BRPI0510428A (pt) | composições tópicas de metadona e processos para utilização das mesmas | |
WO2004050033A3 (en) | Method of treating cancers | |
BRPI0518255A2 (pt) | mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica | |
BRPI0518281A2 (pt) | inibidores de 11-beta hidroxilesteràide desidrogenase do tipo i e mÉtodos uso dos mesmos | |
BRPI0515316A (pt) | compostos de imidazoquinolina | |
BRPI0618552B8 (pt) | compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos | |
TW200612987A (en) | Combination treatment for non-hematologic malignancies | |
MY143795A (en) | Tetrahydropyridoindole derivatives | |
PA8580201A1 (es) | Terapia de combinacion para enfermedades hiperproliferativas | |
BRPI0512535A (pt) | compostos de piperidinas n-substituìdas, suas composições e métodos de modulações | |
BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
CR9987A (es) | Compuestos de lactama y métodos de uso de los mismos | |
BR0007430A (pt) | Composição tópica compreendendo n-acetilaminoácidos ou n-acetilaldosaminas | |
BRPI0207961B8 (pt) | uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
BRPI0500704A (pt) | composições de tratamento pessoal reidratáveis | |
BR0100046A (pt) | Copolìmeros reticulados solúveis em água ou intumescìveis em água | |
DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
BR0311939A (pt) | composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico | |
TR201903587T4 (tr) | Telomeraz aktivitesinin artırılması için bileşimler. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE(S) |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011. |